Erste Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | $9.62M | Buy |
29,810
+6,500
| +28% | +$2.1M | 0.08% | 205 |
|
2025
Q1 | $6.26M | Sell |
23,310
-3,200
| -12% | -$859K | 0.08% | 204 |
|
2024
Q4 | $6.31M | Buy |
26,510
+10,000
| +61% | +$2.38M | 0.08% | 215 |
|
2024
Q3 | $4.54M | Sell |
16,510
-12,000
| -42% | -$3.3M | 0.05% | 250 |
|
2024
Q2 | $7.04M | Hold |
28,510
| – | – | 0.09% | 184 |
|
2024
Q1 | $4.4M | Hold |
28,510
| – | – | 0.06% | 241 |
|
2023
Q4 | $5.58M | Hold |
28,510
| – | – | 0.08% | 204 |
|
2023
Q3 | $4.96M | Hold |
28,510
| – | – | 0.09% | 204 |
|
2023
Q2 | $5.45M | Hold |
28,510
| – | – | 0.1% | 206 |
|
2023
Q1 | $5.56M | Hold |
28,510
| – | – | 0.11% | 195 |
|
2022
Q4 | $6.79M | Sell |
28,510
-2,420
| -8% | -$576K | 0.14% | 165 |
|
2022
Q3 | $6.48M | Sell |
30,930
-5,000
| -14% | -$1.05M | 0.15% | 172 |
|
2022
Q2 | $5.23M | Hold |
35,930
| – | – | 0.12% | 195 |
|
2022
Q1 | $5.94M | Sell |
35,930
-870
| -2% | -$144K | 0.11% | 196 |
|
2021
Q4 | $6.26M | Hold |
36,800
| – | – | 0.11% | 185 |
|
2021
Q3 | $6.53M | Sell |
36,800
-5,800
| -14% | -$1.03M | 0.13% | 175 |
|
2021
Q2 | $7.07M | Hold |
42,600
| – | – | 0.14% | 167 |
|
2021
Q1 | $5.76M | Hold |
42,600
| – | – | 0.14% | 168 |
|
2020
Q4 | $5.56M | Sell |
42,600
-13,000
| -23% | -$1.7M | 0.15% | 165 |
|
2020
Q3 | $8.06M | Sell |
55,600
-15,500
| -22% | -$2.25M | 0.28% | 106 |
|
2020
Q2 | $10.5M | Hold |
71,100
| – | – | 0.42% | 77 |
|
2020
Q1 | $7.74M | Sell |
71,100
-5,200
| -7% | -$566K | 0.45% | 64 |
|
2019
Q4 | $8.97M | Buy |
76,300
+1,400
| +2% | +$165K | 0.4% | 64 |
|
2019
Q3 | $6.07M | Buy |
74,900
+11,800
| +19% | +$957K | 0.32% | 85 |
|
2019
Q2 | $4.49M | Hold |
63,100
| – | – | 0.24% | 111 |
|
2019
Q1 | $5.72M | Hold |
63,100
| – | – | 0.32% | 83 |
|
2018
Q4 | $4.33M | Buy |
+63,100
| New | +$4.33M | 0.29% | 88 |
|